CAR-T Therapy: Supporting Evidence and Value Considerations
Although CAR-T therapies have shown favorable response rates, they can be incredibly costly and may not be priced in alignment with their benefits.
Hematologic Cancer
HEMATOLOGIC CANCER ADVISOR
FEATURED CONTENT
-
-
The FDA Approval Process Needs Refinement, Not a Total Overhaul
Even though overall drug development times have not changed, questions about the clinical benefit of the drugs that have been approved through expedited pathways are being raised. -
How Durable Are Responses to Targeted Therapies Across Single-Arm Cancer Trials?
Drugs approved based on changes to surrogate biomarker levels may be subject to measurement bias, according to investigators. -
Reporting Mechanisms for Conflict of Interest Disclosures in Medicine Need Standardization
ASCO officials examined the discrepancies in financial disclosures across platforms and call for a simplified system. -
Trabectedin Targets Leukemic Cells and Restores Immune Cell Function in Models of Chronic Lymphocytic Leukemia
This study led to the first clinical trial in humans to test trabectedin for CLL.
HEMATOLOGIC CANCER NEWS
Ofatumumab May Prolong Survival in Relapsed Chronic Lymphocytic Leukemia
Phase 2 Trial of Ibrutinib, Bortezomib, Dexamethasone Combination for R/R Multiple Myeloma Was Closed Early
No Link Found Between Hepatitis C Infection and Extrahepatic Cancers
Long-Term Follow-Up of R-CHOP and Rituximab Maintenance in Elderly Patients With Mantle Cell Lymphoma
Asciminib Shows Clinical Activity for Pretreated CML in Phase 1 Trial
Want to read more?
Please login or register first to view this content.
Next post in Hematologic Cancers
